Cargando…
Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study
BACKGROUND: Psoriasis is a chronic and refractory skin disease. The emergence of biologics provides more options for the treatment of psoriasis, but the COVID-19 pandemic poses challenges for the management of psoriasis. OBJECTIVES: The purpose of this study was to investigate the effect of differen...
Autores principales: | Huang, Dawei, Yu, Yingyuan, Lu, Jiajing, Tan, Fei, Shi, Yuling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657819/ https://www.ncbi.nlm.nih.gov/pubmed/38020100 http://dx.doi.org/10.3389/fmed.2023.1280965 |
Ejemplares similares
-
A prospective randomized half-body study: 308 nm LED light vs. 308 nm excimer laser for localized psoriasis
por: Yu, Yingyuan, et al.
Publicado: (2023) -
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015) -
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021) -
Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016) -
IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
por: Shi, Yuling, et al.
Publicado: (2019)